Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12315886 | 0.93 | OPRL1 (0.39) | NOTUMAXLCSNK1DMERTKSLC18A3 | |
| SCHEMBL12315905 | 0.90 | NOTUM (0.41) | NOTUMAXLCSNK1DMERTKSLC18A3 | |
| SCHEMBL12315903 | 0.90 | CHRM1 (0.45) | NOTUMAXLCSNK1DMERTKSLC18A3 | |
| SCHEMBL13000592 | 0.90 | NOTUM (0.56) | NOTUMAXLCSNK1DMERTKSLC18A3 | |
| SCHEMBL12316029 | 0.90 | KDM1A (0.46) | NOTUMAXLCSNK1DMERTKSLC18A3 | |
| SCHEMBL12315910 | 0.89 | CHRM1 (0.39) | NOTUMAXLCSNK1DMERTKSLC18A3 | |
| SCHEMBL12315904 | 0.89 | CHRM1 (0.40) | NOTUMAXLCSNK1DMERTKSLC18A3 | |
| SCHEMBL12315896 | 0.87 | NOTUM (0.44) | NOTUMAXLCSNK1DMERTKSLC18A3 | |
| SCHEMBL12084676 | 0.87 | GRM5 (0.37) | NOTUMAXLCSNK1DMERTKFGFR1 | |
| SCHEMBL12338508 | 0.86 | CHRM1 (0.43) | NOTUMAXLCSNK1DMERTKSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227614-A1 | Modulators of Muscarinic Receptors | CHRM5, CHRM3, CHRM2 | NOTUM 1978/4885AXL 1690/4885CSNK1D 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.